Navigation Links
Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
Date:8/30/2012

RICHMOND, Calif., Aug. 30, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:50 pm ET on Thursday, September 6, 2012, at the Stifel Nicolaus Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
3. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
4. Sangamo BioSciences Reports First Quarter 2012 Financial Results
5. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Neurocrine Biosciences Reports Second Quarter 2012 Results
10. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
11. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
(Date:7/31/2020)... CAMBRIDGE, Mass. and SOMERSET, N.J (PRWEB) , ... ... ... a leading genome editing company, and Catalent, the leading global provider of advanced ... and consumer health products, today announced that they have entered into a strategic ...
(Date:7/31/2020)... , ... July 30, 2020 ... ... cloud-based software for the life sciences industry, today announced the release of ... designed specifically for Medical Science Liaisons (MSLs) and other field medical professionals. ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said Matt Hundt, ... market and we were pleased that the IFT jury recognized that.” reFRESH™ couples the ... natural way to extend the shelf life and improve the safety of perishable foods ...
Breaking Biology Technology:
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode scheduled for ... Point of Care Testing solutions (POCT). Check local listings for more info. , Today, ... offices and are shipped to labs throughout the country. Results are then available several ...
(Date:6/23/2020)... , ... June 23, 2020 ... ... of gene-to-protein and monoclonal antibody development services, today announced that the company ... and services to the pharmaceutical, diagnostics, and research industries. The decision to ...
(Date:6/23/2020)... ... ... The field of quantitation of large molecules or proteins has been around ... the use of mass spectrometry in this field has gained a lot of momentum ... choose which approach to use (LBA or MS)?” In many cases, either technology ...
Breaking Biology News(10 mins):